Adjuvant immunotherapy in high-risk stage II melanoma: real-world outcomes from a large multicenter retrospective study
{{output}}
Background: Cutaneous melanoma (CM) is an aggressive cancer since early stages. Stage IIB/C CM present significant recurrence risk. Recently, adjuvant immunotherapy demonstrated to increase recurrence-free survival (RFS) in this ... ...
